Survival and prognostic factors in malignant pleural mesothelioma: A retrospective study of 314 patients in the west part of Japan

Japanese Journal of Clinical Oncology

Volumn 41, Issue 1, 2011, Pages 32-39

  Nojiri, Shuko ^a   Gemba, Kenichi ^b   Aoe, Keisuke ^c   Kato, Katsuya ^d   Yamaguchi, Takuhiro ^e   Sato, Tsugumichi ^f   Kubota, Kiyoshi ^a   Kishimoto, Takumi ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL INSTITUTE OF OCCUPATIONAL SAFETY AND HEALTH   (Japan)

^c NATIONAL SANYO HOSPITAL   (Japan)

^d OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f NPO (Nonprofit Organization) Drug Safety Research Unit Japan   (Japan)

Author keywords

Malignant mesothelioma; Prognostic factor; Retrospective study and survival

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; MALE; MESOTHELIOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLEURAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650794570     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq159     Document Type: Article

References (25)

1. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 1982;96:746-55.
2. Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988;6:527-35.
3. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging. Cancer 1993;72:394-404.
4. Kanazawa N, Ioka A, Tsukuma H, Ajiki W, Oshima A. Incidence and survival of mesothelioma in Osaka, Japan. Jpn J Clin Oncol 2006;36:254-7.
5. Hasegawa S, Tanaka F. Malignant mesothelioma: current status and perspective in Japan and the world. Gen Thorac Cardiovasc Surg 2008;56:317-23.
6. Baas P. Predictive and prognostic factors in malignant pleural mesothelioma. Curr Opin Oncol 2003;15:127-30.
7. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-53.
8. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-52.
9. Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Laroze A, Ginsberg R, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989;7:1157-68.
10. Van Gelder T, Damhuis RA, Hoogsteden HC. Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J 1994;7:1035-8.
11. Nakano K, Shiota Y, Ono T, Taniyama K, Hiramoto T, Yamakido M. Clinico-pathological prognostic factors in malignant pleural mesothelioma. Nihon Kokyuki Gakkai Zasshi 2007;45:153-9 (in Japanese).
12. Umeki S, Kawai S, Hino J, Adachi M, Yagi S, Soejima R. Prognostic factors in cases of diffuse malignant pleural mesothelioma. Nihon Kyobu Shikkan Gakkai Zasshi 1989;27:768-76 (in Japanese).
13. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991;102:1-9.
14. Raghunathan TE, Lepkowski JM, VanHoewyk J, Solenberger P. A muitivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 2001;27:85-95.
15. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: Wiley, 1987.
16. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-31.
17. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000;55:731-55.
18. Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer SJ, Lee TH, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993;11:1172-8.
19. Hulks G, Thomas JS, Waclawski E. Malignant pleural mesothelioma in western Glasgow 1980-6. Thorax 1989;44:496-500.
20. Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka R, Jost E. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie 2008;31:665-70.
21. Mantovani G. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer 2003; 11:494-5.
22. Ishihara K, Hasegawa T, Okazaki M, Katakami N, Sakamoto H, Lee E, et al. OK432 chemical pleurodesis as a standard therapy of spontaneous pneumothorax. Nihon Kyobu Shikkan Gakkai Zasshi 1988;26:10-5 (in Japanese).
23. Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-65.
24. Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma J Thorac Oncol 2006;1:175-6.
25. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 1990;13:4-9.